布鲁姆维:复发性多发性硬化症治疗的突破:一篇评论
Ayesha Azhar1, Muskan Asim Taimuri1, Shamat Fathi Shamat1
1Department of Internal Medicine, Dow University of Health Sciences.
Annals of medicine and surgery (2012)
|October 9, 2023
概括
布里姆维 (ublituximab) 是一种新的抗CD20抗体疗法,用于治疗多发性硬化症 (MS). 临床试验表明,与特里弗卢诺米德相比,它显著降低了复发率,提供了一个有前途的MS治疗选择.
科学领域:
- 神经免疫学 神经免疫学
- 自免疫性疾病 自免疫性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
- 虽然传统上涉及T细胞,但B细胞现在被认为是MS病理生理学的关键参与者.
- 针对B细胞,特别是CD20阳性细胞,已经成为MS的治疗策略.
研究的目的:
- 评估Briumvi (ublituximab) 作为一种新的B细胞疗法,用于复发性多发性硬化症的疗效和安全性.
- 为了比较ublituximab与teriflunomide在减少疾病活性方面的有效性.
主要方法:
- 进行了两项随机,双盲的III期临床试验 (ULTIMATE I和II).
- 对抗CD20单克隆抗体的ublituximab进行了静脉注射,并与teriflunomide进行了比较.
- 这些试验评估了关键的疗效终点,包括年度复发率.
主要成果:
- 在ULTIMATE II试验中,乌布利图西马布的复发率与特里弗卢诺米德相比明显较低.
- 布鲁姆维向CD20阳性B细胞,导致其枯竭和免疫反应调节.
- 与输液相关的反应是最频繁报告的副作用.
结论:
- 布里姆维 (ublituximab) 代表了B细胞治疗复发性多发性硬化症的重大进展.
- 该药物在降低复发率方面的有效性支持其在治疗多发性硬化症方面的作用.
- 对管理输液相关反应的进一步研究可能会提高患者的耐受性.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...